术前应用雷珠单抗对增生型糖尿病视网膜病变患者行玻璃体切除术的影响
2021-11-18封彦龙宋玫侠
封彦龙 宋玫侠



摘 要 目的:探讨术前应用雷珠单抗对增生型糖尿病视网膜病变(proliferative diabetic retinopathy, PDR)患者行玻璃体切除术的影响。方法:将进行择期玻璃体切除术且术前接受雷珠单抗治疗的83例(83眼)PDR患者作为雷珠单抗组,未接受雷珠单抗治疗的67例(67眼)PDR患者作为单纯手术组,对其临床资料进行回顾性分析。结果:雷珠单抗组手术时间、电凝例数、硅油、气体填充率及医源性裂孔发生率均显著少于单纯手术组(P<0.05);经治疗两组视力、眼压及黄斑中心凹视网膜厚度均得到显著改善,且治疗后雷珠单抗组各指标均显著优于单纯手术组,术后并发症发生率显著低于单纯手术组(均P<0.05)。结论:对择期进行玻璃体切除术治疗的PDR患者术前采用雷珠单抗处理可显著提升手术效果及术中医源性损伤,同时可降低术后并发症的发生,安全有效。
关键词 增生期糖尿病视网膜病变 23G微创玻璃体切割术 雷珠单抗
中图分类号:R988.1; R587.2 文献标志码:A 文章编号:1006-1533(2021)21-0037-03
Effect of preoperative application of ranibizumab on vitrectomy in patients with proliferative diabetic retinopathy
FENG Yanlong, SONG Meixia
(Department of Ophthalmology, the 988 Hospital of Joint Logistics Support Force, Zhengzhou 450042, China)
ABSTRACT Objective: To investigate the effect of ranibizumab on vitrectomy in patients with proliferative diabetes retinopathy (PDR). Methods: Eighty-three patients (83 eyes) with PDR were included in a ranibizumab group (underwent elective vitrectomy and treated with ranibizumab before operation) and 67 patients (67 eyes) with PDR were included in an operation group (without ranibizumab treatment). The clinical data were retrospectively analyzed. Results: The operation time, the cases of electrocoagulation, the filling rate of silicone oil and gas and the incidence of iatrogenic hiatus were significantly lower in the ranibizumab group than the operation group (P<0.05). After treatment, visual acuity, intraocular pressure and macular foveal retinal thickness in both groups were significantly improved, and furthermore all indexes were significantly better and the incidence of postoperative complications was significantly lower in the ranibizumab group than the operation group (all P<0.05). Conclusion: Preoperative treatment with ranibizumab for PDR patients undergoing vitrectomy can significantly improve the surgical effect and iatrogenic injury during the operation, reduce the occurrence of postoperative complications and are safe and effective.
KEy wORDS proliferative diabetic retinopathy; 23G minimally invasive vitrectomy; ranibizumab
增生型糖尿病視网膜病变(proliferative diabetic retinopathy, PDR)是一种常见的糖尿病性微血管病变导致的并发症,严重影响患者生活。手术是PDR的重要治疗手段,但大量新生血管的存在给手术带来诸多风险。本研究将血管内皮生长因子(vascular endothelial growth factor, VEGF)抑制剂雷珠单抗应用于择期进行玻璃体切除术的PDR患者中,旨在探讨术前应用雷珠单抗在PDR玻璃体切除术患者中的应用效果,为PDR患者治疗方案的制定提供更多依据,现报道如下。
1 资料与方法
1.1 一般资料
本研究将2018年5月—2020年5月在我院进行择期玻璃体切除术且术前接受雷珠单抗治疗的83例(83眼)PDR患者作为雷珠单抗组,患者玻璃体出血3个月以上或反复出血;黄斑区有大量视网膜前出血;玻璃体出血伴或不伴局部视网膜脱离;牵引性视网膜脱离或孔源性视网膜脱离可累及黄斑区。将同期在我院进行择期玻璃体切除术且术前未接受雷珠单抗治疗的67例(67眼)PDR患者作为单纯手术组。……
